Literature DB >> 19874254

Bimatoprost - a review.

A Jayaprakash Patil1, Thasarat S Vajaranant, Deepak P Edward.   

Abstract

Bimatoprost is a synthetic prostamide analog that is efficacious in the treatment of open-angle glaucoma, ocular hypertension and other forms of glaucoma. It reduces intraocular pressure (IOP) by increasing uveoscleral and trabecular outflow. When used as a 0.03% topical preparation once daily, it demonstrates sustained lowering of IOP of 7 - 8 mmHg over a 24-h period. The drug has been found to be more effective than timolol. In some studies it has shown greater ability to lower IOP when compared with other prostaglandin analogs; whereas in others all three clinically used prostaglandin analogs were found to be equally effective. It shows good IOP reduction when used in combination with other glaucoma medications. A common side effect includes mild conjunctival hyperemia, which is generally reversible. Other side effects include periorbital pigmentation, discomfort, ocular surface hyperemia and skin changes. Pharmacoeconomic data indicate that bimatoprost is cost effective in the treatment of open-angle glaucoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874254     DOI: 10.1517/14656560903292649

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

Review 1.  Effects of prostaglandin analogues on aqueous humor outflow pathways.

Authors:  Nelson S Winkler; Michael P Fautsch
Journal:  J Ocul Pharmacol Ther       Date:  2013-12-20       Impact factor: 2.671

2.  Innovative approaches to glaucoma management of Boston keratoprosthesis type 1.

Authors:  Thasarat S Vajaranant; Jessica Liu; Jacob Wilensky; M Soledad Cortina; Ahmad A Aref
Journal:  Curr Ophthalmol Rep       Date:  2016-07-26

3.  Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits.

Authors:  Abayomi B Ogundele; Mark C Jasek
Journal:  Clin Ophthalmol       Date:  2010-12-07

4.  Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.

Authors:  Kaidi Wang; Li Xu; Zhilan Yuan; Ke Yao; Junmei Zhao; Liang Xu; Aiwu Fang; Mingzhi Zhang; Lingling Wu; Jian Ji; Jiamin Hou; Qing Liu; Xinghuai Sun
Journal:  BMC Ophthalmol       Date:  2014-02-25       Impact factor: 2.209

Review 5.  Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution.

Authors:  Daniel Lee; Anand V Mantravadi; Jonathan S Myers
Journal:  Clin Ophthalmol       Date:  2017-07-10

Review 6.  Challenges of Glaucoma Management in Patients with Type I Boston Keratoprosthesis.

Authors:  Sara M AlHilali; Samar A Al-Swailem
Journal:  Clin Ophthalmol       Date:  2022-02-11

7.  Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two "challenging" case reports.

Authors:  Caterina Palleria; Christian Leporini; Serafina Chimirri; Giuseppina Marrazzo; Sabrina Sacchetta; Lucrezia Bruno; Rosaria M Lista; Orietta Staltari; Antonio Scuteri; Francesca Scicchitano; Emilio Russo
Journal:  J Pharmacol Pharmacother       Date:  2013-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.